Skip to main content
. 2020 Dec 23;23(7):1100–1112. doi: 10.1093/neuonc/noaa298

Fig. 2.

Fig. 2

Fig. 2

Survival associations with intrathecal and systemic pharmacotherapy per LM subtype. Numbers of patients treated with intrathecal (A,C) or systemic (E,G) pharmacotherapy per LM subtype and corresponding survival (B,D,F,H) (Type I: A, B, E, F; Type II: C, D, G, H).